NCT06636591View on ClinicalTrials.gov

Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer

NARecruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

November 18, 2024

Primary Completion Date

February 7, 2025

Study Completion Date

October 7, 2026

Conditions
Breast Cancer FemaleHER2-negative Breast Cancer
Interventions
COMBINATION_PRODUCT

Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin

Drugs was given a few days after multimodal thermal therapy

COMBINATION_PRODUCT

Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin Drug: Goserelin

Drugs was given a few days after multimodal thermal therapy

Trial Locations (1)

200032

RECRUITING

Breast cancer institute of Fudan University Cancer Hospital, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER